In Silico Development of a Multi-epitope Vaccine Targeting TFDP3: A Novel Approach for Cancer Immunotherapy
Cell Biochemistry and Biophysics · 2025
DOI: 10.1007/s12013-025-01830-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell Biochemistry and Biophysics, 2025. Verfasst von Genilda Castro de Omena Neta und 7 weiteren Autor:innen. Beteiligte Einrichtung: Federal University of Alagoas, Arapiraca, Alagoas, Brazil. Hauptthemen laut MEDLINE: Cancer Vaccines, Immunotherapy, Epitopes, Computer Simulation. Die Arbeit nennt 103 Literaturangaben. Gefördert von: Alagoas State Research Support Foundation.
Abstract (Originalsprache)
The increase in cancer incidence and mortality demonstrates the need for more effective anti-tumor therapies. Targeted therapies, such as cancer testicular antigens (CTAs), are promising as they are expressed in tumor cells but not in normal cells. TFDP3, a CTA expressed in cancers such as triple-negative breast cancer, prostate cancer, childhood T-cell lymphoblastic leukemia, and hepatocellular carcinoma, was chosen as a target for vaccine development. This study aimed to predict a multi-epitope vaccine based on TFDP3 using immunoinformatics tools to identify antigenic epitopes that interact with B lymphocytes, CD4+T lymphocytes, and CD8+T lymphocytes. Three epitopes from each lymphocyte type were selected, considering factors such as antigenicity, allergenicity, toxicity, IFN-γ induction, and population coverage. The vaccine also included adjuvants and ligands that ensure the stability and proper processing of the epitopes. The in-silico analysis revealed that the vaccine has favorable physicochemical properties, low homology with human proteins, and interactions with Toll-like receptors, ensuring stability. The population coverage world of the MHC class I and II epitopes were 93.55%. Additionally, the vaccine can be cloned and induce a robust immune response after three administrations. Despite the promising results, immunotherapy still faces challenges, such as tumor heterogeneity and immune evasion. In vitro and in vivo studies are necessary to assess the vaccine's efficacy and safety for future cancer treatments that express TFDP3.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Federal University of Alagoas, Arapiraca, Alagoas, Brazil.
- Federal Institute of Alagoas, Satuba, Alagoas, Brazil.
- Oswaldo Cruz Foundation of Rondonia (FIOCRUZ/RO), Porto Velho, RO, Brazil.
- Institute of Biological and Health Sciences, Federal University of Alagoas, Maceió, Brazil.
- Federal University of Alagoas, Arapiraca, Alagoas, Brazil. carlos.fraga@arapiraca.ufal.br.
Förderung
- Alagoas State Research Support Foundation
Zitieren
APA
de Omena Neta, G. C., da Silva Junior, J. W. B., Rocha, R. M. L., da Silva Fernandes Duarte, A. K., Gomes, E. S. B., Zanchi, F. B., de Sales Marques, C., & de Carvalho Fraga, C. A. (2025). In Silico Development of a Multi-epitope Vaccine Targeting TFDP3: A Novel Approach for Cancer Immunotherapy. Cell Biochemistry and Biophysics. https://doi.org/10.1007/s12013-025-01830-2
Vancouver
de Omena Neta GC, da Silva Junior JWB, Rocha RML, da Silva Fernandes Duarte AK, Gomes ESB, Zanchi FB, et al. In Silico Development of a Multi-epitope Vaccine Targeting TFDP3: A Novel Approach for Cancer Immunotherapy. Cell Biochemistry and Biophysics. 2025. doi:10.1007/s12013-025-01830-2
BibTeX
@article{deOmenaNeta2025,
author = {de Omena Neta, Genilda Castro and da Silva Junior, Jose Wilson Batista and Rocha, Rodger Marcel Lima and da Silva Fernandes Duarte, Ana Kelly and Gomes, Emisael Stenio Batista and Zanchi, Fernando Berton and de Sales Marques, Carolinne and de Carvalho Fraga, Carlos Alberto},
title = {In Silico Development of a Multi-epitope Vaccine Targeting TFDP3: A Novel Approach for Cancer Immunotherapy},
journal = {Cell Biochemistry and Biophysics},
year = {2025},
doi = {10.1007/s12013-025-01830-2}
}
EUVIMED